Fig. 2

PGA-C response of clear (0)/almost clear (1) and ≥2 grade improvement at Week 16. *Lower limit 80 % CI of difference tofacitinib versus vehicle >0. Proportion (SE) of patients achieving a PGA-C response of clear (0) or almost clear (1) and ≥2 grade improvement from baseline through to Week 16 for patients applying 2 % tofacitinib, 1 % tofacitinib, or vehicle, once daily (a) or twice daily (b). Patients who were discontinued or with missing values were considered non-responders. BID twice daily, BL baseline, CI confidence interval, PGA-C Calculated Physician’s Global Assessment, PGA-Cm Calculated Physician’s Global Assessment of patients with mild to moderate plaque psoriasis at baseline, QD once daily, SE standard error, tofa tofacitinib